DiaTech Oncology Test Shows Positive Results
News Jun 20, 2013
DiaTech Oncology has developed a predictive test that has been effective in clinical trials in helping oncologists determine the best chemotherapy treatment plans and therapeutic strategies for more than 50 types of cancers. The company has just published detailed results of the clinical trials for mesothelioma lung cancer, small-cell lung cancer (NSCLC) and advanced stage III and IV ovarian cancer at the American Society of Clinical Oncology (ASCO) conference held in Chicago.
The ASCO event, considered the world’s premiere oncology conference, features cutting-edge scientific presentations and attracts more than 25,000 oncology professionals yearly.
In previous clinical trials and published research, DiaTech Oncology’s predictive test – the MiCK® assay or Correct Chemo™ – showed an increase in complete or partial response rates, longer time to relapse and longer survival times for multiple types of cancer, including acute myeloid leukemia, lymphoma and non-Hodgkin lymphoma, and breast, bladder, ovarian, endometrial and lung cancers.
DiaTech has conducted extensive research on patients with ovarian cancer; however, the results published at ASCO were the first for advanced stage III and IV ovarian cancer or ovarian cancer patients who have relapsed and have resistance to one of the most commonly used chemotherapy drugs, carboplatin. Trial results showed that the MiCK assay can identify alternative chemotherapy treatments for ovarian cancer patients who have relapsing disease and carboplatin resistance.
Clinical results published at ASCO for mesothelioma are significantly notable because there are limited therapies currently available for this rare disease, which medical experts regard as one of the most aggressive and deadly of all cancers. The study was able to identify new chemotherapy strategies that could possibly help control mesothelioma in individual patients.
“DiaTech is the only test on the market that guides the treating oncologist to the most effective chemotherapy for inducing cell death in the malignant cells of a particular cancer patient,” says Cary Presant, M.D., DiaTech Chief Medical Officer. “Our clinical tests consistently reveal longer survival times and lower costs for chemotherapy cancer patients. We will carry on in our important work with our key institutional research partners. Our studies are yielding unexpected new leads for innovative therapeutic strategies.“
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
A Mechanism of Drug Resistance in Breast & Ovarian CancerNews
Researchers have discovered the molecular means by which some cancers caused by errors in the gene BRCA1 evade treatment by drugs custom-tailored to kill them.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018